Skip Navigation
  Search Menu
Find an Expert


Shanmugasundaram Ganapathy Kanniappan, Ph.D.

Photo of Dr. Shanmugasundaram Ganapathy Kanniappan, Ph.D.

Assistant Professor of Radiology and Radiological Science

Research Interests: Cancer metabolism; cancer immunotherapy; liver fibrosis


Dr. Ganapathy-Kanniappan is an Assistant Professor in the Department of Radiology & Radiological Science of Johns Hopkins University School of Medicine. Dr. Ganapathy-Kanniappan's research interest includes cancer metabolism and altered energy metabolism in liver fibrosis.

Dr. Ganapathy-Kanniappan obtained his Ph.D degree from the University of Madras and underwent postdoctoral training at premier institutes such as National Institute of Immunology (NII), New Delhi and the University of California at Los Angeles (UCLA). After a fellowship in the Department of Medicine/ Hematology division at Johns Hopkins, he joined the Radiology department as a faculty.

Dr. Ganapathy-Kanniappan has several publications in reputed journals and has written many reviews and a book chapter on cancer metabolism and therapeutic opportunities. more


  • Assistant Professor of Radiology and Radiological Science

Departments / Divisions



  • B.S., University of Madras (India) (1988)
  • Ph.D., University of Madras (India) (1998)

Research & Publications

Research Summary

My primary research interest is to develop effective strategies that can selectively target “altered energy producing pathways” or “metabolic reprogramming” in disease conditions such as cancer and liver fibrosis.

Liver cancer: Our aim is to develop an effective antiglycolytic strategy that can selectively and specifically disrupt tumor metabolism and improve the therapeutic outcome of HCC patients.

Breast cancer: Our goal is to revolutionize treatment regimens by replacing interventions that are challenged by lack of efficacy or increased toxicity”. With my background in cancer metabolism and collaboration with Drs. Bhujwalla and Dr.Wu, we intend to develop a novel framework whereby cancer metabolism could be minimally perturbed to trigger host immune response.

Liver fibrosis: The long term goal is to develop effective therapeutic strategies for liver diseases such as fibrosis/cirrhosis by selective targeting of “energy metabolism” in hepatic stellate cells (HSCs) that exhibit uncontrolled activation.

Selected Publications

View all on Pubmed

Ganapathy-Kanniappan S. Targeting tumor glycolysis by a mitotropic agent. Expert Opin Ther Targets. 2016 Jan;20(1):1-5. PubMed PMID: 26420565.

Kunjithapatham R, Geschwind JF, Devine L, Boronina TN, O'Meally RN, Cole RN, Torbenson MS, Ganapathy-Kanniappan S. Occurrence of a multimeric high-molecular-weight glyceraldehyde-3-phosphate dehydrogenase in human serum. J Proteome Res. 2015 Apr 3;14(4):1645-56. PubMed PMID: 25734908.

Fu D, Geschwind JF, Karthikeyan S, Miller E, Kunjithapatham R, Wang Z, Ganapathy-Kanniappan S. Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. Oncoimmunology. 2015 Jan 14;4(3):e991228. eCollection 2015 Mar. PubMed PMID: 25949910.

Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Clin Cancer Res. 2014 Dec 15;20(24):6406-17. PubMed PMID: 25326230.

Kunjithapatham R, Karthikeyan S, Geschwind JF, Kieserman E, Lin M, Fu DX, Ganapathy-Kanniappan S. Reversal of anchorage-independent multicellular spheroid into a monolayer mimics a metastatic model. Sci Rep. 2014 Oct 29;4:6816. PubMed PMID: 25351825.

Ganapathy-Kanniappan S, Karthikeyan S, Geschwind JF, Mezey E. Is the pathway of energy metabolism modified in advanced cirrhosis? J Hepatol. 2014 Aug;61(2):452. PubMed PMID:24810232.

Karthikeyan S, Geschwind JF, Ganapathy-Kanniappan S. Tumor cells and memory T cells converge at glycolysis: therapeutic implications. Cancer Biol Ther. 2014 May;15(5):483-5. PubMed PMID: 24556820.

Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013 Dec 3;12:152.PubMed PMID: 24298908.

Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget. 2012 Sep;3(9):940-53. Review. PubMed PMID: 22964488.

Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M, Geschwind JF. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology. 2012 Mar;262(3):834-45. PubMed PMID: 22357885.

Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510-7. PubMed PMID: 20420565.

Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Vali M. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258-62. PubMed PMID: 20085459.

Shanmugasundaram GK et al. (2002). Homo sapiens isolate 1 monocyte chemoattractant protein 1 (MCP1) gene, promoter region 310 bp linear DNA. Accession: AF493697.1 GI: 20530673

Shanmugasundaram GK et al. (2002). Homo sapiens isolate 2 monocyte chemoattractant protein 1 (MCP1) gene, promoter region 307 bp linear DNA. Accession: AF493698.1 GI: 20530674

Shanmugasundaram GK et al. (2002). Papio hamadryas monocyte chemoattractant protein 1 (MCP1) gene, promoter region 312 bp linear DNA. Accession: AF493699.1 GI: 20530675

Shanmugasundaram GK et al. (2002). Macaca radiata monocyte chemoattractant protein 1 (MCP1) gene, promoter region 312 bp linear DNA. Accession: AF493700.1 GI: 20530676

Shanmugasundaram GK et al. (2002). Callithrix jacchus monocyte chemoattractant protein 1 (MCP1) gene, promoter region 316 bp linear DNA. Accession: AF493701.1 GI: 20530677

Shanmugasundaram GK, Sundaresan G, Shoeb F, Arumugam N, Kumaravelu J, Unwalla H, Chakraborti S, Banerjea AC. Genetic analyses of cis-acting sequences controlling expression of human immunodeficiency virus type 1 coreceptor-CCR5 gene in rabbits and CXCR4 gene in monkeys. J Hum Virol. 2001 Jul-Aug;4(4):188-94. PubMed PMID: 11694846

Shahi S, Shanmugasundaram GK, Banerjea AC. Ribozymes that cleave reovirus genome segment S1 also protect cells from pathogenesis caused by reovirus infection. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4101-6. Epub 2001 Mar 13. PubMed PMID: 11274435.

Shanmugasundaram GK, Ramamoorti N, Banerjea AC. Novel HIV-1 co-receptor-CCR5 promoter mutations in simians: identification of two highly polymorphic regions with extensive deletions. AIDS. 2000 Sep 29;14(14):2201-2. PubMed PMID: 11061662.

Invited Book Chapter on "Targeting Glycolytic Adaptations in Cancer Cells: From Molecular Mechanisms to Therapeutic Opportunities". Book entitled: "Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics" Edited by Dr.Georg Thomas Wondrak, published by Springer.

Activities & Honors


  • Concept Award, Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP), USA
  • Pilot Research Grant, Society for Interventional Radiology (SIR) foundation, USA
  • Best Presentation Award, National Symposium on Reproductive Biology and Comparative Endocrinology, India
  • Awarded the prestigious Research Fellowship and Lectureship,, CSIR-UGC, Government of India, 1991


  • American Association for Cancer Research

Videos & Media

Lectures and Presentations

  • Targeting Glucose Metabolism: A New Class of Agents against Liver Cancer
    Editorial , 2012 Gastrointestinal Cancers Symposium , San Francisco, CA

Recent News Articles and Media Coverage

Is this you? Edit Profile